(Z)-LFM-A13 NEW
| Price | $30 | $44 | $100 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-27 |
Product Details
| Product Name: (Z)-LFM-A13 | CAS No.: 244240-24-2 |
| Purity: 99.90% | Supply Ability: 10g |
| Release date: 2026/07/27 |
Product Introduction
Bioactivity
| Name | (Z)-LFM-A13 |
| Description | (Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK. |
| In vitro | In BTK+ B-lineage leukemic cells, (Z)-LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. [1] In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels [2] In human neutrophils, (Z)-LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity. [3] |
| In vivo | In BALB/c mice bearing BCL-1 leukemia, combination of(Z)-LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. [2] In primary myeloma-bearing SCID-rab mice,(Z)-LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2.5 mg/mL (6.94 mM), Sonication is recommended. DMSO : 67 mg/mL (186.11 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Polo-like Kinase (PLK) | PLK | LFM-A-13 | LFM-A13 | LFMA13 | LFM A13 | Janus kinase | JAK | Inhibitor | inhibit | BTK | Bruton tyrosine kinase |
| Inhibitors Related | Ruxolitinib | Atinvicitinib | Pyridoxine | Tofacitinib Citrate | Resveratrol | Ibrutinib | 4-Phenoxyphenylboronic acid | Remibrutinib | JAK-IN-10 | 2,4,5-Trimethoxybenzoic acid | Rilzabrutinib | Lentinan |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | JAK-STAT Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-27 | ||
| $1210.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
|
VIP5Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2026-08-05 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-07-30 | ||
| $1.00 |
VIP9Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY